Initially I was very disturbed with the PR regardi
Post# of 72440
As to the upcoming PR giving further trial data on secondary matters and Compassionate Use results, I would like to see the PR written with the CU results given first (as I expect them to be the better of the two) and then follow with whatever data derives from the secondary data. Leo would emphasize the difference in dosage and dosings between the 2 sets of results to show that B is everything it was expected to be but needs to be given at a much higher dosage than was given in the trial and for severe patients possibly many more dosings.
All the above is predicated on the CU results being far better than the trial secondary endpoint results.